William Gregozeski has spent more than 10 years working as an industry-agnostic equity analyst covering securities listed around the world. Gregozeski currently manages the sellside equity research department and oversees U.S. client relationships at Mont Blanc Capital Management, a Zurich-based investment firm. Previous work includes writing sellside research on U.S.-listed small-cap companies at Gar Wood Securities, a Chicago-based broker dealer, and researching the cleantech industry in the U.S. and small-cap China-based companies at Capstone Investments, a San Diego-based broker dealer. Gregozeski is a CFA charterholder, has obtained a bachelor's degree in finance and a master's degree in business administration from Marquette University, and currently holds FINRA Series 7, 24, 66, 79, 86, and 87 licenses.
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity."
The Life Sciences Report Interview with William Gregozeski
"BTI's BT2111 shows significant advantages over Herceptin."
William Gregozeski, Mont Blanc Capital Management